Goldman Sachs reduced their Viropharma VPHM estimates following a release of generic versions of their drug Vanco.
Goldman Sachs went on to say, “…we are reducing our VPHM estimates for 2012-2015. This drives a decrease in our 12-month price target, equally based on our DCF/SOTP analyses, to $22 from $26.”
VPHM closed yesterday at $22.44.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in